Prostate Cancer Risk Stratification Using PDE4D7 Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical risk descriptors fail to effectively delineate the extent or aggressiveness of prostate cancer for all patients, leading to suboptimal primary treatment decisions, particularly in intermediate-risk groups where a significant sub-population faces 10-25% cancer recurrence after primary treatment.
Innovation Solution
A method for pre-surgical risk stratification of prostate cancer using a gene expression profile for phosphodiesterase 4D variant 7 (PDE4D7), which determines an expression-based risk score and combines it with pre-surgical clinical variables to provide a pre-surgical prognostic risk score, guiding treatment decisions between active surveillance and radical intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If clinical risk descriptors are used for pre-surgical risk classification, then treatment decisions can be made, but the risk stratification is insufficient and does not effectively delineate the extent or aggressiveness of prostate cancer for all patients
Solution Approach 1:
The patent transitions from two-dimensional clinical risk classification (based on PSA, Gleason score, and clinical stage) to a three-dimensional risk assessment by adding molecular biomarker data (PDE4D7 expression, PDE4D5/9 ratio, and PDE4D7/PDE4D5 ratio). This dimensional expansion enables finer stratification of prostate cancer risk, allowing differentiation between patients with similar clinical presentations but distinct molecular profiles, thereby improving measurement precision while reducing information loss about disease aggressiveness.
Solution Approach 2:
The patent creates a composite risk assessment model that integrates multiple data types: clinical variables (PSA, Gleason score, clinical stage), molecular biomarkers (PDE4D7 expression, PDE4D5/9 ratio, PDE4D7/PDE4D5 ratio), and calculates composite risk categories (very low, low, intermediate, high, very high risk). This composite approach synthesizes heterogeneous information sources into a unified risk stratification system that captures both clinical and molecular aspects of prostate cancer, resolving the contradiction between clinical classification simplicity and comprehensive risk assessment.
2Object-affected harmful factors
If active surveillance is recommended for very low and low risk prostate cancer, then treatment-related morbidity is reduced, but a significant sub-group (10-25%) experiences cancer recurrence after primary treatment
Solution Approach 1:
The patent applies local quality by identifying specific molecular sub-groups within the very low and low risk categories that have distinct recurrence risks. By analyzing PDE4D7 expression levels and PDE4D5/9 ratios, the system identifies patients with high-risk molecular features who should receive active treatment despite having low clinical risk scores. This localized differentiation allows treatment customization at the molecular level, reducing unnecessary treatment-related morbidity in true low-risk patients while improving reliability by targeting treatment to those with high molecular-risk features who are prone to recurrence.
Solution Approach 2:
The patent introduces molecular biomarkers (PDE4D7 expression, PDE4D5/9 ratio, PDE4D7/PDE4D5 ratio) as intermediary elements between clinical risk assessment and treatment decision-making. These biomarkers serve as mediators that reveal hidden risk stratification within clinical categories, enabling clinicians to identify patients who would benefit from active treatment despite low clinical risk scores. The biomarkers act as intermediaries that bridge the gap between clinical presentation and actual disease behavior, allowing for more reliable treatment selection while maintaining low morbidity by avoiding overtreatment of truly low-risk patients.
3Device complexity
If intermediate risk group is treated as a homogeneous population, then treatment simplification is achieved, but the group is heterogeneous with varied outcomes including aggressive pathological characteristics
Solution Approach 1:
The patent segments the intermediate risk group into distinct molecular sub-groups based on PDE4D7 expression levels and PDE4D5/9 ratios. This segmentation reveals that intermediate risk patients are not homogeneous but comprise sub-populations with different molecular profiles and outcome patterns. By dividing the heterogeneous intermediate risk group into molecularly-defined sub-groups, the system maintains manageable treatment classification complexity while significantly improving outcome predictability within each segment, as patients within the same molecular sub-group have more consistent treatment responses.
Data Source
AI summary
The invention relates to a method of pre-surgical risk stratification of a prostate cancer subject, comprising determining a gene expression profile for phosphodiesterase 4D variant 7 (PDE4D7) in a biological sample obtained from the subject, determining gene expression profile, and determining a pre-surgical prognostic risk score for the subject based on the expression based risk score and pre-surgical clinical variables of the subject. This may allow for an improved stratification of the subject in a pre-surgical setting that may result in better primary treatment decisions. For instance, the pre-surgical prognostic risk score may allow to make better recommendation on whether to select active surveillance vs. active intervention, e.g., radical prostatectomy, for certain sub-populations of prostate cancer patients.